Immuno-oncology moves beyond PD-1

Nat Biotechnol. 2015 Jul;33(7):673-5. doi: 10.1038/nbt0715-673.
No abstract available

Publication types

  • News

MeSH terms

  • Animals
  • Antibodies, Monoclonal* / immunology
  • Antibodies, Monoclonal* / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents* / immunology
  • Antineoplastic Agents* / therapeutic use
  • Dendritic Cells / immunology
  • Drug Industry
  • Humans
  • Immunotherapy / trends*
  • Lymphocytes / immunology
  • Mice
  • Neoplasms* / drug therapy
  • Neoplasms* / immunology
  • Nivolumab
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors
  • Signal Transduction / immunology

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Programmed Cell Death 1 Receptor
  • Nivolumab
  • pembrolizumab